MSD to create 200 new jobs in Carlow, Cork and Tipperary
Expansion reflects critical role of MSD’s Irish sites in wider global network.
MSD will create 200 new jobs across three of its Irish manufacturing sites by the end of 2016. Due to continued growth and an increase in the supply of products to the global market from Ireland, MSD is recruiting experienced professionals for positions based at MSD’s locations in Carlow, Cork and Tipperary.
The new roles span Operations, Quality, Engineering, Supply Chain, and Commercial Operations.
Ger Carmody, Associate Vice President, and Site Lead at MSD in Ballydine, Tipperary, said: “Today’s announcement reflects the critical role MSD’s Irish sites play in our wider global manufacturing network. Those taking up these new roles will be at the cutting edge of healthcare innovation and will play a key role in delivering MSD’s overall ambition to preserve and improve human life. Our state-of-the-art facilities in Carlow, Cork and Tipperary are leading the way in the development of new medicines, including MSD’s new treatments for cancer and hepatitis C, which are being manufactured in Ireland for the world market. Today, our Irish sites are involved in the production of over 60% of MSD’s global top 20 products.”
MSD in Carlow, the company’s only standalone vaccine and biologics facility outside the US, is creating 110 new roles spanning production, engineering and quality control. MSD in Brinny, Co. Cork, which specialises in the fermentation and sterile filling of biotech products, is seeking 50 new hires in manufacturing, quality, technology, engineering and environmental & safety. Finally, MSD in Ballydine, Co. Tipperary, which is involved in the R&D, formulation and manufacture of active pharmaceutical ingredients, will recruit 40 new employees, including process and chemical engineers and organic chemists by year end.
Recognised as Ireland’s Pharma Company and Biopharma Company of the Year in 2015, MSD already employs over 2,000 people across five sites in Ireland – in Dublin, Carlow, Cork, Tipperary and Wicklow. Its extensive Irish operations, encompassing manufacturing, commercial, global financial services and marketing facilities, had a turnover of €3 billion in 2014. MSD has a strong legacy in Ireland that stretches back over the last 50 years, and in that time, the company has invested over $2.5 billion in expanding and developing its facilities here. The company provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immunology, oncology, infectious diseases, women’s health and anaesthesia.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance